Vera Therapeutics Stock Performance
| VERA Stock | USD 49.75 0.92 1.88% |
On a scale of 0 to 100, Vera Therapeutics holds a performance score of 9. The entity has a beta of 1.65, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vera Therapeutics will likely underperform. Please check Vera Therapeutics' skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Vera Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Vera Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Vera Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.88 | Five Day Return 4.76 | Year To Date Return 218.71 | Ten Year Return 332.61 | All Time Return 332.61 |
1 | Disposition of 6351 shares by Fordyce Marshall of Vera Therapeutics at 37.7753 subject to Rule 16b-3 | 09/11/2024 |
2 | Disposition of 13823 shares by Seidenberg Beth C of Vera Therapeutics at 42.3058 subject to Rule 16b-3 | 09/19/2024 |
3 | Disposition of 900 shares by Fordyce Marshall of Vera Therapeutics at 46.79 subject to Rule 16b-3 | 09/25/2024 |
4 | Disposition of 3352 shares by Fordyce Marshall of Vera Therapeutics at 38.8312 subject to Rule 16b-3 | 10/09/2024 |
5 | Disposition of 600 shares by Fordyce Marshall of Vera Therapeutics at 41.6127 subject to Rule 16b-3 | 10/23/2024 |
6 | Vera Therapeutics Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years | 10/28/2024 |
7 | Vera Therapeutics director Beth Seidenberg sells shares for 720,493 | 10/30/2024 |
8 | Vera Therapeutics to Participate at Upcoming Investor Conferences | 11/08/2024 |
9 | Disposition of 1875 shares by Fordyce Marshall of Vera Therapeutics at 49.4992 subject to Rule 16b-3 | 11/13/2024 |
10 | COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc | 11/15/2024 |
11 | Vera Therapeutics Stock Price Down 4.6 percent Heres Why | 11/18/2024 |
12 | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 11/22/2024 |
13 | Disposition of 1875 shares by Fordyce Marshall of Vera Therapeutics at 49.0 subject to Rule 16b-3 | 11/25/2024 |
| Begin Period Cash Flow | 43.8 M |
Vera |
Vera Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,836 in Vera Therapeutics on September 3, 2024 and sell it today you would earn a total of 1,139 from holding Vera Therapeutics or generate 29.69% return on investment over 90 days. Vera Therapeutics is currently generating 0.4765% in daily expected returns and assumes 3.7923% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Vera, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vera Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vera Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vera Therapeutics, and traders can use it to determine the average amount a Vera Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1256
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VERA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.79 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.48 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Vera Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vera Therapeutics by adding it to a well-diversified portfolio.
Vera Therapeutics Fundamentals Growth
Vera Stock prices reflect investors' perceptions of the future prospects and financial health of Vera Therapeutics, and Vera Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vera Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 2.85 B | ||||
| Shares Outstanding | 63.32 M | ||||
| Price To Earning | 17.01 X | ||||
| Price To Book | 10.90 X | ||||
| Revenue | 1.86 M | ||||
| EBITDA | (102.01 M) | ||||
| Net Income | (95.99 M) | ||||
| Cash And Equivalents | 131.93 M | ||||
| Cash Per Share | 4.86 X | ||||
| Total Debt | 53.71 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 8.24 X | ||||
| Book Value Per Share | 5.25 X | ||||
| Cash Flow From Operations | (92.18 M) | ||||
| Earnings Per Share | (2.61) X | ||||
| Market Capitalization | 3.15 B | ||||
| Total Asset | 175.55 M | ||||
| Retained Earnings | (309.1 M) | ||||
| Working Capital | 149.72 M | ||||
| Current Asset | 237.64 M | ||||
| Current Liabilities | 54.04 M | ||||
About Vera Therapeutics Performance
By analyzing Vera Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Vera Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vera Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vera Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 617.74 | 549.10 | |
| Return On Tangible Assets | (0.55) | (0.57) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.55) | (0.57) | |
| Return On Equity | (0.94) | (0.90) |
Things to note about Vera Therapeutics performance evaluation
Checking the ongoing alerts about Vera Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vera Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.86 M. Net Loss for the year was (95.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vera Therapeutics currently holds about 131.93 M in cash with (92.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86. | |
| Over 95.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 1875 shares by Fordyce Marshall of Vera Therapeutics at 49.0 subject to Rule 16b-3 |
- Analyzing Vera Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vera Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Vera Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vera Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vera Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vera Therapeutics' stock. These opinions can provide insight into Vera Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vera Stock analysis
When running Vera Therapeutics' price analysis, check to measure Vera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vera Therapeutics is operating at the current time. Most of Vera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vera Therapeutics' price. Additionally, you may evaluate how the addition of Vera Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |